AFT Crystawash reg'n in China and new licencing agreements

Monday 27th March 2023

AFT gains first product registration in China with Crystawash Extend and extends Maxigesic IV licensing

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces its achievement of registration for sale of its long-lasting hand sanitiser Crystawash® Extend in China.

AFT also announces it has signed further new licence agreements for the intravenous dose form of its Maxigesic pain relief medicine as it continues to build momentum in its international business.

The Chinese National Medical Products Administration (NMPA) approved Crystawash Extend – 24-hour long-lasting hand sanitiser which allows AFT to sell into retail stores in mainland China. Crystawash Extend sanitises and protects against 99.99% of germs for up to 24 hours. It is non-toxic & alcohol-free. AFT will commercialise this product range within the next 6 to12 months into mainland China.

The privately owned Swiss pharmaceutical company Labatec has licensed the intravenous form, Maxigesic IV®, in Switzerland. Labatec and AFT are aiming for registration and launch of the medicine - a treatment for mild to moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally – in the next 12 to 18 months.

Pharma Bavaria has extended its existing Maxigesic IV licence agreement in Latin America to include Argentina and Paraguay in addition to the licences already agreed with AFT for the medicine in Bolivia, Chile, Columbia, Ecuador, Peru, Uruguay.

The agreements build on launches of Maxigesic IV since the start of the year in the Netherlands, Denmark, Sweden, Norway, and Finland.

AFT Managing Director Dr Hartley Atkinson said: “These licensing, registration and distribution agreements and the recent launches will add to the growing momentum we are seeing in the company’s international business.

“As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in March 2022, although just short of our target of 63 countries. We are pleased with the progress we are making in realising the potential of our Maxigesic intellectual property. Additionally, we are pleased to achieve our first product registration in Mainland China and further registrations are pending.”

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232

Released for and on behalf of AFT Pharmaceuticals by Malcolm Tubby, Chief Financial Officer

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com

About Labatec

Labatec is a privately owned Swiss-based pharmaceutical company based out of Geneva, Switzerland with an operational hub in Portugal. Labatec is present in the Swiss market in addition to the Middle East North Africa markets, selling over 100 products in the Hospital and Speciality retail segments. For more information visit: www.labatecpharma.com/

About Pharma Bavaria

Pharma Bavaria International Group distributes and promotes high-quality pharmaceuticals with well-researched ingredients in more than 45 countries. With a strong focus on growth regions such as the Middle East, Africa, South-East Asia, CIS countries and other emerging economies Pharma Bavaria’s portfolio of prescription medicines includes anti-infectives, analgesic/anti-allergic/anti-inflammatory, flu and cold, gastroenterology, oncology, cardiology, and women’s healthcare brands and is rounded off with a range of OTC products. For more information visit: www.pharma-bavaria.com.

200327 registrations and licenses

Comments from our readers

No comments yet